Weekly Spotlight - 31.10.24

In the News

Biogen's Phase 2 Success in IgA Nephropathy Drug Development

Biogen's Phase 2 trial data for felzartamab highlights its potential to positively impact IgA nephropathy treatment. This promising development joins Biogen's portfolio of treatments advancing kidney care, while Sanofi's parallel investment in obesity biotech signals broader patient-focused initiatives in chronic disease management.

Oxford Classification Predicts IgA Nephropathy Outcomes in Children

A new study supports the Oxford Classification as a predictive tool for kidney outcomes in children with IgA nephropathy, particularly noting specific lesions (M, S, T, C) associated with poorer prognoses. This classification aids physicians in personalising treatment strategies and improving patient care for paediatric IgA nephropathy.

Long-term Options for IgA Nephropathy Management

Jonathan Barratt discusses Nefecon's efficacy in long-term IgA nephropathy management, with promising outcomes for re-dosing protocols. The open-label study shows sustained reduction in proteinuria without safety issues, providing hope for lasting symptom control and improved quality of life for patients with IgA nephropathy.

Coping Strategies for Stress in Rare Kidney Disease Patients

Ginger Murphy shares her journey with rare kidney disease, highlighting stress as a major factor. She manages it through yoga, walking, and spending time with grandkids. Stress impacts her health, but she finds relief in emotional release and relaxation techniques, maintaining a positive outlook despite challenges.

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!